Lupin acquires nine brands of Medical Nutritional Institute in South Africa
Company expands its presence in the complementary and alternative medicines sector
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Lupin
Lupin signs distribution agreement with scope Ophthalmics for eye care products in Mexico
Lupin to distribute OPTASE range, addressing dry eyes and related conditions in Mexican market
Lupin partners with Celnova Pharma to distribute NaMuscla in Argentina and Colombia
NaMuscla (mexiletine) to be commercialised for the treatment of non-dystrophic myotonic disorders in adults
Lupin gets US FDA nod for Bumetanide Injection, USP
Bumetanide Injection USP (RLD Bumex) had estimated annual sales of $ 20 million in the US (IQVIA MAT July 2024)
Lupin partners with Takeda to commercialise Vonoprazan
The drug will be marketed under the brand name Lupin’s Lupivon and will be available in two strengths - 10 mg and 20 mg
Manufacturing the right talent
As pharma manufacturing evolves to meet dynamic market demands, regulatory shifts and technological advancements,Kavita Jani…
Sunsure Energy and Lupin sign 21 MW solar power purchase agreement
Sunsure to supply solar energy to Lupin’s Tarapur facility as part of its ongoing decarbonisation strategy
Lupin launches Mirabegron Extended-Release Tablets in the US
Mirabegron Extended-Release Tablets, 50 mg had estimated annual sales of $ 1,600 million in the US (IQVIA MAT July 2024)
Making sustainability sustainable
Driven by stringent regulations, rising investor expectations, consumer demand, and operational considerations, Viveka…
Lupin launches Doxorubicin Hydrochloride Liposome Injection in the United States
Lupin expands oncology portfolio with the launch of a generic version of Doxil in the U.S.